ARMYDA TICA-MI study

You likely can't join if

• - Any conditions that, in the opinion of the investigator, contraindicates antiplatelet therapy or would have an unacceptable risk of bleeding. - Clinically significant ongoing bleeding. - Injuries or conditions that significantly increase the risk of major bleeding (these may include recent or ongoing gastric ulceration, presence of cancer with high risk of bleeding, recent brain or spinal trauma, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular dysfunctions). - Hypersensitivity to the active substance or to any of the excipients. - Known end stage renal disease on hemodialysis. - Known severe hepatic dysfunction. - Acute or severe bronchial asthma or upper airway obstruction. - Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin. - Treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) within 7 days. - Treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxoban) within 7 days. - Known platelet count <100x106/mL. - Known hemoglobin <10 g/dL. - Known hematocrit < 28% - Pregnancy (to be ascertained with pregnancy tests in women of childbearing potential) and breastfeeding. - Inability to provide informed consent.